- Home
- ORI vs ROIV Comparison
ORI vs ROIV Comparison
Compare ORI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORI | ROIV |
|---|---|---|
| Founded | 1923 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ORI | ROIV |
|---|---|---|
| Price | $42.78 | $21.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $49.00 | $24.31 |
| AVG Volume (30 Days) | 1.4M | ★ 8.3M |
| Earning Date | 01-22-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $8,748,900,000.00 | $20,329,000.00 |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $6.10 | $741.42 |
| P/E Ratio | $12.83 | ★ N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $33.00 | $8.73 |
| 52 Week High | $46.76 | $23.47 |
Technical Indicators
Market Signals| Indicator | ORI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | 51.18 |
| Support Level | $41.81 | $20.78 |
| Resistance Level | $44.26 | $22.21 |
| Average True Range (ATR) | 0.71 | 0.64 |
| MACD | -0.48 | -0.17 |
| Stochastic Oscillator | 20.30 | 28.79 |
Price Performance
Historical ComparisonAbout ORI Old Republic International Corporation
Old Republic International Corp offers a diverse range of specialized insurance products to individuals and institutions. The company operates in two segments: Specialty Insurance and Title Insurance. The Insurances provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.